Zobrazeno 1 - 10
of 2 219
pro vyhledávání: ''
Autor:
Alexis B. Cortot, Didier Debieuvre, L. Moreau, Radj Gervais, Jacques Margery, Julien Mazieres, Olivier Molinier, Michel Poudenx, Alexandra Langlais, Nicolas Girard, Patrick Dumont, Gérard Zalcman, Franck Morin, Virginie Westeel, Pierre-Jean Souquet, Eric Pichon, Fabrice Barlesi, Maurice Pérol, Jérôme Dauba, Jacques Cadranel, Clarisse Audigier-Valette, Denis Moro-Sibilot
Publikováno v:
Lung Cancer. 164:84-90
Benefit from maintenance in advanced non-squamous non-small cell lung cancer (NS-NSCLC) might favor switch maintenance after disease stabilization (SD) and continuation after objective response (OR). This trial assessed a maintenance strategy conditi
Autor:
Tomoko Yoshida, Kazuhiko Takeda, Toshihiko Kaneda, Hiroaki Yanagimoto, Takao Yoshida, Kayoko Kibata, Koji Tsuta, Takayasu Kurata, Hiroshige Yoshioka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Background Immune checkpoint inhibitors prolong the survival of non-small cell lung cancer (NSCLC) patients. Although it has been acknowledged that there is some correlation between the efficacy of anti-programmed cell death-1 (PD-1) antibody therapy
Autor:
Minoru, Horiuchi, Tetsuya, Oguri, Yusuke, Kagawa, Kazuki, Sone, Satoshi, Fukuda, Takehiro, Uemura, Osamu, Takakuwa, Ken, Maeno, Kennsuke, Fukumitsu, Yoshihiro, Kanemitsu, Tomoko, Tajiri, Hirotsugu, Ohkubo, Masaya, Takemura, Yutaka, Ito, Akio, Niimi
Publikováno v:
Anticancer Research. 42:1073-1079
The optimal chemotherapy for concurrent chemoradiotherapy (cCRT) of lung cancer is still unclear.We investigated the therapeutic effect of different chemotherapy regimens for cCRT of lung cancer in 65 patients at our hospital.Of the 65 patients, 53 w
Autor:
Ariadna Juarez-Garcia, John C O'Donnell, John R. Penrod, Mats Rosenlund, Simon Ekman, Jens Benn Sørensen, Anne Mette Kejs, Pia Horvat, L. Lacoin, Odd Terje Brustugun, Dony Patel, M. Daumont
Publikováno v:
Sørensen, J B, Horvat, P, Rosenlund, M, Kejs, A M, Patel, D, Juarez-Garcia, A, Lacoin, L, Daumont, M J, Penrod, J R, O'donnell, J C, Brustugun, O T & Ekman, S 2022, ' Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015) : SCAN-LEAF study ', Future Oncology, vol. 18, no. 2, pp. 205-214 . https://doi.org/10.2217/fon-2021-0746
Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagn
Autor:
Atsushi Nakamura, Shunsuke Teraoka, Naohisa Matsumoto, Kazuhiko Nakagawa, Akito Hata, Satoshi Ikeda, Nobuyuki Yamamoto, Motohiro Tamiya, Shinya Sakata, Satoru Miura, Kentaro Ito, Hiroshige Yoshioka, Yoshimasa Shiraishi, Shota Omori, Junko Tanizaki, Koji Haratani, Hisako Yoshida, Kohei Otsubo
Publikováno v:
Cancer Science
Considering the increasing number of identified driver oncogene alterations, additional genetic tests are required to determine the treatment for advanced non‐small‐cell lung cancer (NSCLC). Next‐generation sequencing can detect multiple driver
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Denisa Rozsivalova, Jana Alahakoon, Juraj Kultan, Andrea Mullerova, Kristián Brat, Daniel Krejci, Ondrej Venclicek, Libor Havel, Martin Svaton, Martina Vasakova, Petra Smickova, Ondrej Fischer, Kristyna Hrda, Jana Skrickova, Zsuzsanna Gyorfy, Miloslav Marel, Gabriela Krakorova, P. Opálka, Michal Hrnčiarik, Jaroslav Duba, Jiri Silar, Michal Svoboda, Michal Jirousek, Petr Zuna, J. Krejčí, Lydia Zarnayova
Publikováno v:
Anticancer Research. 41:5549-5556
Background/aim LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018.
Autor:
Steven Kao, Tessa A. Morris, Mark Voskoboynik, Benjamin Solomon, Luke McLean, Wasek Faisal, Ross Jennens, Sagun Parakh, Craig R. Lewis, Malinda Itchins, Adam R. Broad, Melvin Chin
Publikováno v:
JCO Precision Oncology. :561-568
PURPOSE Leptomeningeal disease (LMD) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma is associated with a poor prognosis and limited treatment options. Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor with
Autor:
Takaaki Tokito, Akihiro Bessho, Satoshi Igawa, Shinji Sasada, Nobuhiko Seki, Naoki Furuya, Yosuke Tanaka, Koichi Minato, Kaoru Kubota, Hideki Hayashi, Hirotoshi Iihara, Rintaro Noro, Takayuki Kaburagi, Tsuneo Shimokawa, Hiroaki Okamoto, Masanao Nakashima, Shingo Miyamoto, T. Hirose, Toshiyuki Harada
Publikováno v:
Lung Cancer. 161:49-54
Objectives Afatinib is an effective treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, the toxicity associated with this agent often leads to dose modifications. The aim
Autor:
Chih Bin Lin, Chao Hua Chiu, Kang Yun Lee, Wen Hui Ku, Yen-Ting Lin, Yu-Feng Wei, Shang Yin Wu, Jian Su, Mei Hsuan Lee, Jen Yu Hung, Jin-Yuan Shih, Chi Lu Chiang, Hsin Pei Chung, Wu Chou Su, Yen Han Tseng, Tsai Shin Chiang
Publikováno v:
European Journal of Cancer. 156:1-11
Introduction Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib are approved for advanced non–small-cell lung cancer (NSCLC) with ALK rearrangement. However, the mechanism